Recommendations of the Spanish society of nephrology for managing bone-mineral metabolic alterations in chronic renal disease patients;Recomendaciones de la sociedad Española de nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica

Nefrologia

Volumn 28, Issue SUPPL. 1, 2008, Pages 1-22

  Torregrosa, José Vicente ^a   Andia, Jorge Cannata ^b   Bover, Jordi ^c   Caravaca, Francisco ^d   Lorenzo, Víctor ^e   De Francisco, Ángel Luis Martín ^f   Martín Malo, Alejandro ^g   Martínez, Isabel ^h   Parra, Emilio González ⁱ   Glráldez, Elvira Fernández ^j   Portillo, Mariano Rodríguez ^g  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c FUNDACIÓ PUIGVERT   (Spain)

^d HOSPITAL INFANTA CRISTINA   (Spain)

^e Hospital Clínico Universitario   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h Clinical Neurophysiology Unit   (Spain)

ⁱ HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^j HOSPITAL ARNAU DE VILANOVA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; CHRONIC KIDNEY FAILURE; DISORDERS OF MINERAL, ELECTROLYTE AND METAL METABOLISM; ELECTROLYTE DISTURBANCE; HUMAN; METABOLIC BONE DISEASE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE;

ALGORITHMS; BONE DISEASES, METABOLIC; CALCIUM METABOLISM DISORDERS; HUMANS; KIDNEY FAILURE, CHRONIC; PHOSPHORUS METABOLISM DISORDERS;

EID: 50949102694     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (113)

1. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: 1-201, 2003.
2. National Kidney Foundation. K/DOQI. Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. Am J Kidney Dis 35 (Supl. 2):S1-S140, 2000.
3. Moe S, Drueke T, Cunningham J y cols. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from. Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953, 2006.
4. th Edition. Brenner BM (editor). W. B. Saunders Company, pp. 2103-2186, 2000.
5. Martinez I, Saracho R, Montenegro J, Llach F. A déficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant .11 (Supl. 3): 22-8, 1996.
6. Hsu CH, Patel SR. Uremic toxins and vitamin D metabolism. Kidney Int 62: s65-8, 1997.
7. Rodriguez ME y cols. The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Renal Physiol 292: 1390-5, 2007.
8. Qunihi WY. Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD). Kidney Int 90: S8-S12, 2004.
9. Ganesh SK, Stack AG, Levin NW y cols. Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001.
10. Stevens LA, Djurdjev O, Cardew S y cols. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism, and outcomes. J Am Soc Nephrol 15: 770-799, 2004.
11. Block GA, Cunningham J. Morbidity and mortality associated with abnormalities in bone and mineral metabolism in CKD. En: Olgaard K (ed). Clinical Guide to the Basics of Bone and Mineral Metabolism in CKD. chapter 4 National Kidney Foundation: New York, pp. 77-92, 2006.
12. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis Jun; 35 (6): 1226-37, 2000.
13. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 (8): 2206-16, 2004.
14. Cunningham J. Osteoporosis in Chronic-Kidney Disease. Am J Kidney Dis 43: 566-571, 2004.
15. Rodríguez-Benot A, Martín-Malo A, Álvarez-Lara MA, Rodríguez M., Aljama P. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 46: 68-77, 2005.
16. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001.
17. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism an outcomes. J Am Soc Nephrol 15:770-779, 2004.
18. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS Waves 1, 3, and 4 study. J Am Soc Nephrol 16: 1788-1793, 2005.
19. Martin KJ, Olgaard K, Coburn JW y cols. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 43: 558-565, 2004.
20. Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, Cukketon BF. Hemodialysis Clinical Practice Guidelines for the Canadian Society of Nephrology: Mineral Metabolism. J Am Soc Nephrol. 17: Supl. 1 S11-S16, 2006.
21. González Parra E, Arenas MD, Valencia J, Angoso M. Monitorizacion del paciente en hemodiálisis. Nefrología 26 (Supl. 8): 34-53, 2006.
22. Torres A, Lorenzo V, Hernández D y cols. Bone disease in predialysis, hemodialysis and CAPD patients: evidence of a better bone response to PTH. Kidney Int 47: 1434-42, 1995.
23. Autier P y cols. Vitamin D supplementation and Total Mortality. A meta-analysis of randomized controlled trials. Arch Int Med 167 (16): 1730-1737, 2007.
24. Adragao T y cols. A simple vascular calcification score predicts cardiovascular risk in hemodialysis patients. Nephrol Dial Transplant 19: 1480-8, 2004.
25. Yamaguchi T y cols. Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone 19: 549-55, 1996.
26. Ureña P y cols. Bone mineral density, biochemical markers and skeletal fractures in hemodialysis patients. Nephrol Dial Transplant 18; 2325-31, 2003.
27. Kopple JD y cols. Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. Kidney Int 52 (3): 776-191, 1997.
28. Rufino M., Lorenzo V y cols. Is it possible to control, hyperphosphatemia with diet, without inducing protein malnutrition? Nephrol Dial Transplant 13 (Supl. 3): 65-67, 1998.
29. Lorenzo V, Torres A. Tratamiento Conservador de la Insuficiencia Renal Crónica. Medidas generales y manejo dietético. En: Hernando L (Editor): Nefrología Clínica. Editorial Panamericana, Madrid, 1997.
30. Lorenzo V, Rufino M, Martín M. Aspectos nutricionales en hemodiálisis. En: Valderrábano F (Ed): Tratado de Hemodiálisis. Editorial Médica JIMS SL, Barcelona, pp. 339-349, .1999.
31. Martínez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathy-roidism of patients with, early renal failure. Am J Kidney Dis 29 (4): 496-502, 1997.
32. Martínez I, Saracho R, Ocharán J, Muñoz RJ, Montenegro J. Role of diet in the management of osteodystrophy during progressive renal insufficiency. Nefrologia 23 (Supl. 2): 57-63, 2003.
33. Giovannucci E. Can vitamin D reduce total mortality? Arch Int Med 167 (16): 1709-1710, 2007.
34. Hathcock JN, Shao A, Vieth R, Heaney R. Risk, assessment of vitamin D. Am J Clin Nutr 85(1): 6-18, 2007.
35. Wolf M, Shah A, Gutiérrez O y cols. Vitamin D leevls and early mortality among inident hemodialysis patients. Kidney Int 2007.
36. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 289: 8-28, 2005.
37. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 69: 33-43, 2006.
38. Teng M, Wolf M, Lowrie E y cols. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456, 2003.
39. Cheng S, Coyne D. Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease. Expert Opin Pharmacother 7: 617-21: 2006.
40. Cardus A y cols. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 22: 860-6, 2007.
41. Charra B, Chozot C, Jean G y cols. Long 3 × 8 hr dialysis: a three-decode summary. J Nephrol (S7): S64-S69, 2003.
42. Leypoldt JK. Kinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment frequency and duration. Semin Dial 18: 401-408, 2005.
43. Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A. Control of serum, phosphate without any phosphate binders in patients treated with nocturnal, hemodialysis. Kidney Int 53:1399-1404, 1998.
44. Sigrist MK, Devlin L, Taal MW, Fluck RJ, McIntyre CW. Length of interdialytic interval influences serum calcium and phosphorus concentrations. Nephrol Dial Transplant 20: 1643-1646, 2005.
45. Lindsay RM, Al-Hejaili F, Nesrallah G. Calcium and phosphate balance with quotidian hemodialysis. Am J Kidney Dis 42 (Supl. 1): S24-S29, 2003.
46. Walsh M, Culleton B, Tonelli M, Manns B. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int 67: 1500-1508, 2005.
47. Maduell F, Navarro V, Torregrosa E y cols. Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration. Kidney Int 64: 305-313, 2003.
48. Zehnder C, Gutzwiller JP, Renggli K. Hemodiafiltration - a new treatment option for hyperphosphatemia in hemodialysis patients. Clinical Nephrology 52: 152-159, 1999.
49. Locatelli F, Buoncristiani U, Canaud B, Kohler H, Petitclerc T, Zucchelli P. Dialysis dose and frequency. Nephrol Dial Transplant 20: 285-296, 2005.
50. Pflanz S, Henderson IS, McElduff N, Jones MC. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrol Dial Transplant 9: 1121-1124, 1994.
51. Qunibi WY, Hootkins RE, McDowell LL y cols. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65: 1914-1926, 2004.
52. Almirall J, Valenzuela MP. The safety of phosphate binders. Expert Opin Drug Saf 5: 675-86, 2006.
53. Schucker JJ, Ward KE. Hyperphosphatemia and phosphate binders. Am J Health Syst Pharm 62: 2355-61, 2005.
54. Block GA y cols. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438-41: 2007.
55. Suki WN, Zabaneh R, Cangiano JL y cols. Effects of sevelamer and calcium-basel phosphate binders on mortality in hemodialysis patients. Kidney Int 72: 1130-7, 2007.
56. Freemont AJ. Lanthanum carbonate. Drugs Today 42: 759-70, 2006.
57. Block GA, Martin KJ, De Francisco AL y cols. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004.
58. De Francisco ALM. Cinacalcet HCL: a novel therapeutic for hyperparathyroidism. Expert Opinion on Pharmacotherapy 6: 441-452, 2005.
59. Schmitt CP, Odenwald T, Ritz E. Calcium, calcium regulatory hormones, and calcimimetics: impact on cardiovascular mortality. J Am Soc Nephrol Apr; 17 (4): S78-pubmed.
60. Block GA, Martin KJ, De Francisco AL y cols. Cinacalcet for secondary hyperparathy-roidism in patients receiving hemodialysis. N Engl J Med 350 (15): 1516-1525, 2004.
61. MIittman N, Finkelstein F, Culleton B y cols. Cinacalcet HCl (Sensipar') for the Management of Secondary Hyperparathyroidism (HPT) in Patients Receiving Peritoneal Dialysis (PD). J Am Soc Nephrol 15: 280, 2004.
62. Chertow GM, Blumenthal S, Turner S y cols. Cinacalcet hydrochloride in hemodialysis patients on active Vitamine D derivatives with contolled PTH and elevated calcium x phosphorus. Clin J Am Soc Nephrol 1 (2): 305-12, 2006.
63. Julián BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 325: 544-550, 1991.
64. Horber FF, Casez JP, Steiger U, Czerniak A, Montandon A, Jaeger P. Changes in bone mass early after kidney transplantation. J Bone Min Res 9: 1-9, 1994.
65. Almond MK, Kwan JTC, Evans K, Cunningham J. Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron 66: 52-57, 1994.
66. Grotz WH, Mundinger FA, Gugel B y cols. Bone mineral density after kidney transplantation. Transplantation 59: 982-986, 1995.
67. Pichette V, Bonnardeaux A, Prudhomme L, Gagne M., Cardinal J, Ouimet D. Long term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis 28: 105-114, 1996.
68. Grotz WH, Mundinger FA, Rasenack J, Speidel L, Olschewski M, Exner VM, Scollmeyer PJ. Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Nephrol Dial Transplant 10: 2096-2100, 1995.
69. Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 13: 551-558, 2002.
70. Torregrosa JV, Campistol JM, Montesinos M y cols. Factors involved in the loss of bone mineral density after renal transplantation. Transplant Proc 27: 2224-2225, 1995.
71. Torregrosa JV, Campistol JM, Montesinos M y cols. Evolution of bone mineral density after renal transplantation. Nephrol Dial Transplant 10 (S6): 111-113, 1995.
72. Carlini RG, Rojas E, Weisinger JR, López M, Martinis R, Arminio A, Bellorin-Font E. Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 36: 160-165, 2000.
73. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents on the skeleton. J Bone Min Res 11: 1-7, 1996.
74. Cueto-Manzano AM, Konel S, Hutchison AJ y cols. Bone loss in long-term renal transplantation: histopathology and densitometry analysis. Kidney Int 55: 2021-2029, 1999.
75. Roe SD, Porter C.J, Godber IM y cols. Reduced bone mineral density in male renal transplant recipients: evidence for persisting hyperparathyroidism. Osteoporosis Int 16: 142-148, 2005.
76. O'Shaughnessy EA, Dahl DC, Smith CL y cols. Risk factors for fractures in kidney transplantation. Transplantation 74: 362-366, 2002.
77. Durieux S, Mercadal L, Orcei P y cols. Bone mineral density and fracture prevalence in long-term kidney graft recipient. Transplantation 74: 496-500, 2002.
78. Sambrook P. Alfacalcidol and calcitriol in the prevention of bone loss after organ transplantation. Calcif Tissue Int 65: 341-343, 1999.
79. Torres A, García S, Gómez A y cols.: Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 65: 705-712, 2004.
80. De Sevaux RG, Hoitsma AJ, Crstens FH y cols. Treatment with vitamin D y calcium, reduces bone loss after renal transplantation: a randomized study. J Am Soc. Nephrol. 13: 1608-1614, 2002.
81. El-Agroudy AE, El-Husseini AA, El-Sayed M y cols. Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol 14: 2975-2979, 2003.
82. Josephson MA, Schumm LP, Chiu MY y cols. Calcium, and calcitriol prophylaxis attenuates postransplant bone loss. Transplantation 78: 1233-1236, 2004.
83. Coco M, Glicklich D, Claude M y cols. Prevention of Bone Loss in Renal Transplant Recipients: a prospective, randomized trial of intravenous Pamidronate. J Am Soc Nephrol 14: 2669-2676, 2003.
84. Fan SLS, Almond MK, Ball E, Evans K, Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 57: 684-690, 2000.
85. Fan SLS, Kumar S, Ginningham J. Long-term effects on bone mineral density of Pamidronate given at the time of renal transplantation. Kidney Int 63: 2275-2279, 2003.
86. Grotz W, Nagel Ch, Poeschel D y cols. Effect of Ibandronate on Bone Loss and Renal Function after Kidney Transplantation. J Am Soc Nephrol 12: 1530-1537, 2001.
87. Haas M, Leko-Mohr Z, Roschger P y cols. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 63: 1130-1136, 2003.
88. Koc M, Tuglular S, Arikan H y cols. Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant Proc 34: 2111-2113, 2002.
89. Giannini S, Dangel A, Carraro G y cols. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 16: 2111-2117, 2001.
90. Torregrosa JV, Moreno A, Gutiérrez A y cols. Alendronate for treatment of renal transplant patients with osteoporosis. Transp Proc 35 (4): 1393-5, 2003.
91. Jeffery JR, Leslie WD, Karpinski ME y cols. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation 76: 1498-1502, 2003.
92. Torregrosa JV y cols. Weekly risedronate in kidney transplant patients with osteopenia. Transplant Int 20; 708-11, 2007.
93. Szwarc I, Argiles A, Garrigue V, Delmas S, Chong G, Deleuze S, Mourad G. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathy-roidism. Transplant 82 (5): 675-680, 2006.
94. Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium, in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 20:1311-1314, 2005.
95. Serra AL, Schwarz AA, Wick FH, Marti HP, Wuthrich RP. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with, persistent hyperparathyroidism. Nephrol Dial Transplant 20: 1315-1319, 2005.
96. Srinivas TR, Schold JD, Womer KL y cols. Improvement in Hypercalcemia with Cinacalcet after Kidney Transplantation. Clin J Am Soc Nephrol 1: 323-326, 2006.
97. Messa P, Sindici C, Cannella G, Miotti V, Risaliti A, Gropuzzo M, Di Loreto PL, Bresadola F, Mioni G. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 54: 1704-1713, 1998.
98. Apostolou T, Damianou L, Kotsiev V, Drakopoulos S, Hadjiconstantinou V. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet. Clin Nephrol 65 (5): 374-377, 2006.
99. Serra AL, Savoca R, Huber AR y cols. Effective control of persistent hyperparathyroidism, with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 22 (2): 577-583, 2007.
100. 99mTc-MIBI and neck ultrasound in patients with secondary hyperparathyroidism, who are candidates for subtotal parathyroidectomy. Eur J Nucl Med Mol. Imaging 33: 467-73, 2006.
101. Llach F. The evolving pattern of calciphylaxis: therapeutic considerations. Nephrol Dial Transplant 16 (3): 448-451, 2001.
102. Llach F. The evolving clinical features of calciphylaxis. Kidney Int 57 (Supl. 85): S122-124, 2003.
103. Fernández E, Torregrosa JV, Zárraga S, Campistol JM. Calcinosis tumoral y calcifilaxis en el trasplantado renal. Nefrologí a 28 (Supl. 2): S77-S83, 1998.
104. Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial 15 (3): .172-186, 2004.
105. Velasco N, MacGregor MS, Innes A, MacKay IG. Successful treatment of calciphylaxis with cinacalcet - an alternative to parathyroidectomy? Nephrol Dial Transplant 21: 1999-2004, 2006.
106. Vassa N, Twardowski ZJ, Campbell J. Hyperbaric Oxigen therapy in calciphylaxis-induced skin necrosis in a peritoneal skin. Am J Kidney Dis 23: 878-881, 1994.
107. Podimow T, Wherrett C, Burns KD. Hyperbaric oxygen in the treatment of calciphylaxis, a case series. Nephrol Dial Transplant 16: 2176-2180, 2001.
108. Basile C, Montanaro A, Masi M, Pati G, De Maio P, Gismondi A. Hyperbaric oxygen therapy in the treatment of calcific uremic arteriolopathy, a case series. J. Nephrol. 15: 676-680, 2002.
109. Price PA, Fous SA, Williamson MK. Bisphosphonates Alendronate and Ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vase Biol 21: 817-824, 2001.
110. Price PA, Omid N, Than NT Williamson MK. The amino bisphosphonate Ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 71: 356-363, 2002.
111. Monney P, Nguyen QV, Perroud H. Rapid improvement of Calciphylaxis after intravenous pamidronate therapy in a patient with, chronic renal failure. Nephrol Dial Transplant 19:2130-2132, 2004.
112. Shiraishi N, Kitamura K, Miyoshi T, Adach M, Kohda Y, Nonoguchi H y cols. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 48: 151-154, 2006.
113. Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulphate. Am J Kidney Dis 43: 1104-1108, 2004.